Aducanumab (Aduhelm) for Alzheimer's disease.
出版信息
Med Lett Drugs Ther. 2021 Jul 12;63(1628):105-106.
PMID:34543258
Abstract
摘要
相似文献
1
Aducanumab (Aduhelm) for Alzheimer's disease.
Med Lett Drugs Ther. 2021 Jul 12;63(1628):105-106.
2
Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.
JAMA Intern Med. 2021 Oct 1;181(10):1276-1278. doi: 10.1001/jamainternmed.2021.4607.
3
Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
J Alzheimers Dis. 2021;84(4):1457-1460. doi: 10.3233/JAD-215275.
4
Controversial Approval of New Drug to Treat Alzheimer's Disease.
Am J Nurs. 2021 Oct 1;121(10):22-23. doi: 10.1097/01.NAJ.0000794244.40800.99.
5
Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
N Engl J Med. 2021 Aug 26;385(9):771-774. doi: 10.1056/NEJMp2111320. Epub 2021 Jul 28.
6
Donanemab (Kisunla) for Alzheimer's disease.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):129-131. doi: 10.58347/tml.2024.1709a.
7
The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1.
J Alzheimers Dis. 2021;82(3):881-882. doi: 10.3233/JAD-210736.
8
Controversial Alzheimer's drug approval could affect other diseases.
Nature. 2021 Jul;595(7866):162-163. doi: 10.1038/d41586-021-01763-9.
9
Comparison table: Drugs for Alzheimer's disease.
Med Lett Drugs Ther. 2022 Aug 22;64(1657):e136-e137.
10
Aducanumab for Alzheimer's disease: A regulatory perspective.
Pharmacol Res. 2021 Sep;171:105754. doi: 10.1016/j.phrs.2021.105754. Epub 2021 Jul 2.
Zotero 插件